

Wholesale Acquisition Cost Information for Colorado Prescribers

PADCEV™ (enfortumab vedotin-ejfv)

Colorado law requires prescription drug manufacturers to disclose in writing to Colorado prescribers the Wholesale Acquisition Cost (“WAC”) of marketed drugs when engaging in prescription drug marketing. This disclosure provides the WAC price for the products listed below.

| NDC | Astellas Product | Dosage Form | Strength | Unit Size | Wholesale Acquisition Cost* |
|--------------|------------------|------------------|----------|-----------|-----------------------------|
| 51144-020-01 | Padcev™ | Single-dose vial | 20 mg | 1 | \$2,192.00 |
| 51144-030-01 | Padcev™ | Single-dose vial | 30 mg | 1 | \$3,288.00 |

The price paid by patients to acquire the products listed is often different than the WAC prices listed, and most patients do not pay WAC. How much a patient will pay will depend on the patient’s insurance coverage. To find out the exact cost of a prescription, patients should contact their health insurance company or preferred pharmacy.

Colorado law also requires manufacturers to provide the names of generic prescription drugs from the same “therapeutic class” as the marketed products. Colorado defines “therapeutic class” as “a group of similar drugs that have the same or similar mechanisms of action and are used to treat a specific condition.” There are currently no generic prescription drugs in the same “therapeutic class” (based on the definition of “therapeutic class” under Colorado law) as the listed product.

*Pricing as of October 1, 2020. The pricing information disclosed above represents the WAC price, which represents the manufacturer’s published catalog or list price for a drug product to wholesalers as reported to third-party drug pricing publishers. WAC does not represent actual transaction prices and does not include discounts, rebates or reductions in price. Pricing information listed does not imply safety or efficacy of the product, and no comparisons should be made.

Padcev™ is a trademark jointly owned by Agensys, Inc. and Seattle Genetics, Inc.